WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1996006162) HYBRIDOMA THAT EXPRESSES mRNA OF INTERLEUKIN-5 AND METHOD OF SCREENING DRUGS THEREWITH
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1996/006162    International Application No.:    PCT/JP1995/001647
Publication Date: 29.02.1996 International Filing Date: 21.08.1995
Chapter 2 Demand Filed:    22.02.1996    
IPC:
C07K 14/54 (2006.01), C12N 5/16 (2006.01)
Applicants: ENVIRONMENTAL RESEARCH INSTITUTE, INC. [JP/JP]; 1-5, Oosaki 5-chome, Shinagawa-ku, Tokyo 141 (JP) (For All Designated States Except US).
OKUDAIRA, Hirokazu [JP/JP]; (JP) (For US Only).
MORI, Akio [JP/JP]; (JP) (For US Only).
MIKAMI, Tadashi [JP/JP]; (JP) (For US Only)
Inventors: OKUDAIRA, Hirokazu; (JP).
MORI, Akio; (JP).
MIKAMI, Tadashi; (JP)
Agent: AOYAMA, Tamotsu; Aoyama & Partners, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 540 (JP)
Priority Data:
6/195031 19.08.1994 JP
Title (EN) HYBRIDOMA THAT EXPRESSES mRNA OF INTERLEUKIN-5 AND METHOD OF SCREENING DRUGS THEREWITH
(FR) HYBRIDOME EXPRIMANT L'ARN MESSAGER DE L'INTERLEUKINE 5, ET PROCEDE DE SELECTION DE MEDICAMENTS FAISANT APPEL A CET HYBRIDOME
Abstract: front page image
(EN)A hybridoma that expresses mRNAs of interleukin-5 and does not produce interleukin-5; and a method of screening antiasthmatic and antiallergic drugs with the hybridoma by utilizing as an index the expression of interleukin-5 genes, particularly, interleukin-5 mRNAs. It is possible to effect screening for developing drugs against diseases such as asthma, delayed allergy and atopic dermatitis by observing the effect of test drugs in inhibiting the expression of interleukin-5 genes with the use of the hybridoma culture system.
(FR)L'invention concerne un hybridome qui exprime des ARN messagers de l'interleukine 5 sans produire celle-ci. L'invention concerne également un procédé permettant de sélectionner des médicaments antiasthmatiques et antiallergiques au moyen dudit hybridome, procédé selon lequel on utilise comme indice l'expression de gènes de l'interleukine 5, en particulier des ARN messagers de l'interleukine 5. Selon l'invention il est possible d'effectuer une sélection dans le but de développer des médicaments destinés à soigner des maladies telles que l'asthme, l'allergie retardée et la dermite atopique, en observant l'effet inhibiteur de l'expression des gènes de l'interleukine 5 produit par des médicaments d'essai, cela au moyen d'un système de culture d'hybridomes.
Designated States: JP, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)